Protalex, Inc. Announces Enrollment of First Patients in 3rd Cohort of Its Ongoing Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthritis
Published: Mar 03, 2011
SUMMIT, N.J., March 3, 2011 (GLOBE NEWSWIRE) -- Protalex, Inc (OTCBB:PRTX), a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, today announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. The dose was increased by a factor of two from the 2nd cohort.